Skip to Content

Interferon alfa-n3 Pregnancy and Breastfeeding Warnings

Interferon alfa-n3 is also known as: Alferon N

Medically reviewed on December 15, 2017

Interferon alfa-n3 Pregnancy Warnings

Abortifacient effects and changes in menstrual cycle have been reported in nonhuman primates when extremely high doses of recombinant interferon alpha were administered intramuscularly. In these studies, abortifacient effects were observed when doses of 978 times the average intralesional dose of interferon alfa-n3 were given.

Interferon alfa-n3 has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of abortifacient effect in rhesus monkeys given interferon alfa-n3 during the early phase of gestation at doses 360 times the maximum recommended dose. There are no controlled data in human pregnancy. Interferon alfa-n3 is only recommended for use during pregnancy when benefit outweighs risk.

See references

Interferon alfa-n3 Breastfeeding Warnings

There are no data on the excretion of interferon alfa-n3 into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue the drug or discontinue nursing, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Alferon N injection (interferon alfa-2a)" Interferon Sciences Inc, New Brunswick, NJ.

References for breastfeeding information

  1. "Product Information. Alferon N injection (interferon alfa-2a)" Interferon Sciences Inc, New Brunswick, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide